. Author manuscript; available in PMC: 2010 Jan 11.

Published in final edited form as: Lancet Infect Dis. 2008 Aug;8(8):498–510. doi: 10.1016/S1473-3099(08)70182-8

Table 3. Novel TB vaccines presently in clinical trials or expected to be in clinical trials within the next 12 months.

Vaccine Name	Construct	Principal	Progress
H1IC	Recombinant fusion protein of ESAT-6 and AG85B in IC31 adjuvant	Subunit vaccine	Completed Phase 1 in the Netherlands, ongoing Phase 1 in Ethiopia ¹⁸²
H1LTK	Recombinant fusion protein of ESAT6 and AG85B in LTK adjuvant, intranasal vaccine	Subunit vaccine	In Phase 1 in the UK ¹⁸³
MTb72f	Recombinant fusion protein of Rv1196 and Rv0125 plus immunostimulant in oil-in-water emulsion	Subunit vaccine	In Phase 1 in Switzerland ¹⁸⁴
Aeras402	Recombinant fusion protein of AG85A, AG85B, TB10.4 coupled with replication-deficient adenovirus-35	Live, non-replicating vector	Completed Phase 1 in USA, Ongoing Phase 1 in South Africa ¹⁸⁵
MVA-85A	Recombinant AG85A expressed through replication-deficient modified vaccinia Ankara	Live, non-replicating vector	Completed phase 1 in UK, Gambia, South Africa, Starting phase 2 in same settings ¹⁸⁶
HyVac 4	Recombinant fusion protein of AG85A plus TB10.4	Subunit vaccine	Expected to start Phase 1 in 2008 ¹⁸⁷
VPM1002	Recombinant BCG vaccine expressing listeriolysin	Live attenuated	Expected to start Phase 1 in 2008 ¹⁸⁸